O	0	14	Administration
O	15	17	of
B-intervention	18	23	omega
I-intervention	23	24	-
I-intervention	24	25	3
I-intervention	26	31	fatty
I-intervention	32	37	acids
I-intervention	38	41	and
I-intervention	42	52	Raloxifene
O	53	55	to
O	56	61	women
O	62	64	at
O	65	69	high
O	70	74	risk
O	75	77	of
O	78	84	breast
O	85	91	cancer
O	91	92	:
O	93	100	interim
O	101	112	feasibility
O	113	116	and
O	117	127	biomarkers
O	128	136	analysis
O	137	141	from
O	142	143	a
O	144	152	clinical
O	153	158	trial
O	158	159	.

O	160	163	The
O	164	176	antiestrogen
O	176	177	,
O	178	188	Raloxifene
O	189	190	(
O	190	193	Ral
O	193	194	)
O	195	197	is
O	198	200	an
O	201	210	effective
O	211	217	breast
O	218	224	cancer
O	225	240	chemopreventive
O	241	246	agent
O	246	247	.

O	248	253	Omega
O	253	254	-
O	254	255	3
O	256	261	fatty
O	262	267	acids
O	268	269	(
O	269	270	n
O	270	271	-
O	271	274	3FA
O	274	275	)
O	276	279	may
O	280	287	inhibit
O	288	295	mammary
O	296	310	carcinogenesis
O	310	311	.

O	312	314	On
O	315	318	the
O	319	324	basis
O	325	327	of
O	328	333	their
O	334	344	mechanisms
O	345	347	of
O	348	354	action
O	354	355	,
O	356	358	we
O	359	363	test
O	364	367	the
O	368	378	hypothesis
O	379	383	that
O	384	385	a
O	386	397	combination
O	398	400	of
O	401	402	n
O	402	403	-
O	403	406	3FA
O	407	410	and
O	411	414	Ral
O	415	418	may
O	419	421	be
O	422	430	superior
O	431	433	in
O	434	442	reducing
O	443	449	select
O	450	460	biomarkers
O	461	463	of
O	464	470	breast
O	471	477	cancer
O	478	482	risk
O	483	485	in
O	486	491	women
O	491	492	.

B-eligibility	493	507	Postmenopausal
I-eligibility	508	513	women
I-eligibility	514	516	at
I-eligibility	517	526	increased
I-eligibility	527	531	risk
I-eligibility	532	535	for
I-eligibility	536	542	breast
I-eligibility	543	549	cancer
O	550	551	(
O	551	557	breast
O	558	565	density
O	566	567	≥
O	568	570	25
O	570	571	%
O	571	572	)
O	573	577	were
O	578	588	randomized
O	589	591	to
O	591	592	:
O	593	594	(
O	594	595	1
O	595	596	)
B-control	597	599	no
I-control	600	612	intervention
O	612	613	;
O	614	615	(
O	615	616	2
O	616	617	)
O	618	621	Ral
O	622	624	60
O	625	627	mg
O	627	628	;
O	629	630	(
O	630	631	3
O	631	632	)
O	633	636	Ral
O	637	639	30
O	640	642	mg
O	642	643	;
O	644	645	(
O	645	646	4
O	646	647	)
O	648	649	n
O	649	650	-
O	650	653	3FA
O	654	655	(
O	655	661	Lovaza
O	661	662	)
O	663	664	4
O	665	666	g
O	667	670	and
O	671	672	(
O	672	673	5
O	673	674	)
O	675	681	Lovaza
O	682	683	4
O	684	685	g
O	685	686	+
O	686	689	Ral
O	690	692	30
O	693	695	mg
O	696	699	for
O	700	701	2
O	702	707	years
O	707	708	.

B-outcome-Measure	709	718	Reduction
I-outcome-Measure	719	721	in
I-outcome-Measure	722	728	breast
I-outcome-Measure	729	736	density
O	737	739	is
O	740	743	the
O	744	751	primary
O	752	755	end
O	756	761	point
O	762	764	of
O	765	768	the
O	769	774	study
O	774	775	.

O	776	778	We
O	779	785	report
O	786	797	preliminary
O	798	802	data
O	803	805	on
O	806	817	feasibility
O	817	818	,
O	819	829	compliance
O	830	833	and
O	834	841	changes
O	842	844	in
O	845	854	secondary
O	855	858	end
O	859	865	points
O	866	873	related
O	874	876	to
O	877	880	IGF
O	880	881	-
O	881	882	I
O	883	892	signaling
O	892	893	,
O	894	902	estrogen
O	903	913	metabolism
O	913	914	,
O	915	924	oxidative
O	925	931	stress
O	932	935	and
O	936	948	inflammation
O	949	951	in
O	952	955	the
O	956	961	first
O	962	967	group
O	968	970	of
B-total-participants	971	973	46
O	974	979	women
O	980	983	who
O	984	993	completed
O	994	995	1
O	996	1000	year
O	1001	1003	of
O	1004	1007	the
O	1008	1013	study
O	1013	1014	.

O	1015	1018	All
O	1019	1032	interventions
O	1033	1037	were
B-outcome	1038	1042	well
I-outcome	1043	1052	tolerated
O	1053	1057	with
O	1058	1067	excellent
B-outcome	1068	1078	compliance
O	1079	1080	(
O	1080	1082	96
O	1083	1084	±
O	1085	1086	1
O	1086	1087	%
O	1088	1095	overall
O	1095	1096	)
O	1097	1099	by
O	1100	1104	pill
O	1105	1110	count
O	1111	1114	and
O	1115	1119	also
O	1120	1129	supported
O	1130	1132	by
O	1133	1136	the
O	1137	1145	expected
O	1146	1150	rise
O	1151	1153	in
O	1154	1158	both
B-outcome	1159	1164	serum
I-outcome	1165	1166	n
I-outcome	1166	1167	-
I-outcome	1167	1170	3FA
I-outcome	1171	1174	and
I-outcome	1175	1176	n
I-outcome	1176	1177	-
I-outcome	1177	1180	3FA
I-outcome	1180	1181	/
I-outcome	1181	1186	Omega
I-outcome	1186	1187	-
I-outcome	1187	1188	6
I-outcome	1189	1194	fatty
I-outcome	1195	1200	acids
I-outcome	1201	1202	(
I-outcome	1202	1203	n
I-outcome	1203	1204	-
I-outcome	1204	1207	6FA
I-outcome	1207	1208	)
I-outcome	1209	1214	ratio
O	1215	1217	in
O	1218	1223	women
O	1224	1234	randomized
O	1235	1237	to
O	1238	1244	groups
O	1245	1246	4
O	1247	1250	and
O	1251	1252	5
O	1253	1254	(
O	1254	1255	P
O	1255	1256	<
O	1256	1257	0
O	1257	1258	.
O	1258	1260	05
O	1260	1261	)
O	1261	1262	.

O	1263	1269	Lovaza
O	1270	1279	decreased
B-outcome	1280	1285	serum
I-outcome	1286	1299	triglycerides
O	1300	1303	and
O	1304	1313	increased
B-outcome	1314	1318	high
I-outcome	1318	1319	-
I-outcome	1319	1326	density
I-outcome	1327	1338	lipoprotein
I-outcome	1339	1340	(
I-outcome	1340	1343	HDL
I-outcome	1343	1344	)
I-outcome	1345	1356	cholesterol
O	1357	1365	compared
O	1366	1370	with
O	1371	1378	control
O	1379	1380	(
O	1380	1381	P
O	1381	1382	<
O	1382	1383	0
O	1383	1384	.
O	1384	1386	05
O	1387	1390	for
O	1391	1395	both
O	1395	1396	)
O	1396	1397	.

O	1398	1401	Ral
O	1402	1409	reduced
B-outcome	1410	1415	serum
I-outcome	1416	1419	IGF
I-outcome	1419	1420	-
I-outcome	1420	1421	1
O	1422	1424	in
O	1425	1426	a
O	1427	1431	dose
O	1431	1432	-
O	1432	1441	dependent
O	1442	1448	manner
O	1449	1450	(
O	1450	1451	P
O	1451	1452	<
O	1452	1453	0
O	1453	1454	.
O	1454	1456	05
O	1456	1457	)
O	1458	1463	while
O	1464	1470	Lovaza
O	1471	1474	did
O	1475	1478	not
O	1478	1479	.

O	1480	1486	Lovaza
O	1487	1490	had
O	1491	1493	no
O	1494	1500	effect
O	1501	1503	on
B-outcome	1504	1507	IGF
I-outcome	1507	1508	-
I-outcome	1508	1509	1
I-outcome	1510	1512	or
I-outcome	1513	1518	IGFBP
I-outcome	1518	1519	-
I-outcome	1519	1520	3
O	1520	1521	.

O	1522	1526	None
O	1527	1529	of
O	1530	1533	the
O	1534	1539	other
O	1540	1550	biomarkers
O	1551	1555	were
O	1556	1564	affected
O	1565	1567	by
O	1568	1571	our
O	1572	1581	treatment
O	1581	1582	.

O	1583	1586	The
O	1587	1598	combination
O	1599	1601	of
O	1602	1608	Lovaza
O	1609	1612	and
O	1613	1616	Ral
O	1617	1619	is
O	1620	1621	a
O	1622	1630	feasible
O	1631	1639	strategy
O	1640	1644	that
O	1645	1648	may
O	1649	1651	be
O	1652	1663	recommended
O	1664	1666	in
O	1667	1673	future
O	1674	1680	breast
O	1681	1687	cancer
O	1688	1703	chemoprevention
O	1704	1710	trials
O	1710	1711	.
